IM Cannabis Clinical Survey Co


Conditions assessed include oncology, PTSD, rheumatoid arthritis, chronic pain, insomnia, back pain, and inflammatory bowel disease

The survey was conducted by a leading cannabis research contract research organization and included more than 650 patients with FDA-validated questionnaires

TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / June 17, 2021 / IM Cannabis Corp. (“IMC” or the “Company”) (NASDAQ: IMCC, CSE: IMCC), a cross-border medical and recreational adult cannabis operator (“MCO”) with offices in Israel, Germany and Canada today has proprietary data presented from a clinical survey evaluating medical cannabis therapy. Medicanl Ltd. (“Medicanl”), an independent international clinical research organization specializing in cannabis research, conducted a patient survey on behalf of IMC found the high effectiveness of seven IMC branded medicinal cannabis strains in treating and relieving symptoms of seven major health conditions in a clinical Group of Israeli participants. The survey data will be used to help patients and clinicians in medical markets around the world adapt cannabis-based therapies to best treat their diagnoses.

The clinical survey included 652 participants and included the following conditions: neuropathic pain, rheumatoid arthritis, oncology, insomnia, back pain, inflammatory bowel disease, and PTSD. The aim was to evaluate the long-term effectiveness of IMC strains, including Roma, Ela, DQ, London, Pandora’s Box, Paris and Tel Aviv (collectively the “IMC Strains”), on patients and their medical conditions, the US American foods and pharmaceuticals use administration-validated questionnaires.

Most important findings:

  • Eighty-one percent of rheumatoid arthritis patients reported improved symptoms.
  • At least 60 percent of patients with neuropathic pain reported improved symptoms.
  • At least 58 percent of back pain sufferers reported improved symptoms.
  • At least 42 percent of PTSD patients reported an improvement in their PTSD scale, which is measured using PCL-5, a validated questionnaire designed to quantify the severity of PTSD symptoms.
  • 38% of insomnia patients reported improved sleep quality based on the Pittsburgh Sleep Quality Index.
  • 60 percent of oncology patients reported an improvement in their general state of health, measured using the “Patient Global Impression of Change” scale.
  • IMC’s Pandora’s Box variety was effective in reducing appetite in patients.
  • All seven IMC strains improved the quality of sleep and increased the patient’s feelings of calm, happiness, and libido.
  • No adverse events were reported with respect to the use of IMC strains.

“While the overall therapeutic benefits of medical cannabis are known and documented, science is still scratching the surface as the global medical community fully understands and realizes the potential of cannabinoids in the treatment of various health conditions,” said Dr. David Meiri, Head of the Laboratory for Cancer Biology and Cannabinoid Research at Technion, Israel Institute of Technology. “The availability of data collected and extracted from these types of clinical surveys, based on FDA-validated questionnaires, while not peer-reviewed or derived from extensive clinical studies, can help clinicians and patients make better use of it and improve – tailor the appropriate cannabis therapy for their specific medical conditions. “

“Having been in the medical cannabis space for over a decade, this invaluable data comes directly from patients thanks to the company’s longstanding relationship with them,” added Oren Shuster, CEO of IMC. “Deeply rooted in science and research, IMC uses this data to ensure that its patients in international markets are getting high quality cannabis products that are best suited to their needs.”

Survey methodology

The clinical survey was commissioned by IMC and conducted in 2020 by an independent contract research organization, Medicanl. The clinical survey included responses from 652 patients between the ages of 19 and 86 who consumed medicinal cannabis (not just IMC strains) on average for more than five years. The survey was conducted using online questionnaires validated by the FDA for the various indications and symptoms, along with demographic data collection in strict compliance with all data protection regulations by the independent third-party provider iPanel Ltd., which used responsive survey methods. The survey included seven IMC proprietary cannabis strains and assessed their effects on treating and relieving symptoms of neuropathic pain, rheumatoid arthritis, oncology, insomnia, back pain, inflammatory bowel disease, and PTSD.

The survey results have not been peer-reviewed or submitted to a leading medical journal. Additional data or studies may be needed to confirm the reported results.

About IM Cannabis Corp.

IMC is an MCO in the field of medicinal and recreational cannabis for adults with headquarters in Israel and offices in Israel, Germany and Canada. Over the past decade, the company believes that the IMC brand has become synonymous with quality and durability in the Israeli medical cannabis market. The company has also expanded its business to provide intellectual property-related services to the medical cannabis industry.

In Europe, IMC is through Adjupharm GmbH (“Adjupharm“), a Germany-based subsidiary and EU-GMP-certified processor and distributor of medical cannabis. IMC’s European presence is complemented by strategic alliances with various European-wide EU-GMP growers and distributors to meet the increased demand for medical cannabis Benefit from cannabis products in Europe and bring the IMC brand and its product portfolio closer to European patients.

In Canada, IMC is through Trichome JWC Acquisition Corp. (“JWC“). JWC is a licensed manufacturer based in Kitchener, Ontario selling cannabis flower, pre-rolls, hash and kief to the Canadian recreational cannabis market under the JWC and Wagners brands. JWC operates to high standards for delivering cleaner, more consistent and aeroponic-grown premium cannabis products for medical patient and adult markets across Canada and the world. On March 31, 2021, IMC entered into a definitive agreement to acquire MYM Nutraceuticals Inc. (“MYM“) and its licensed producer subsidiary Highland Grow Inc. This transaction, if completed, will reinforce IMC’s goal to be a leading global premium cannabis producer and supplier.

Disclaimer for forward-looking statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and US securities laws (collectively “forward-looking informationForward-looking information is often, but not always, identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “likely,” and “intend.” “And statements that an event or outcome” can “,” will “,” should “,” could “or” could “occur or be achieved and other similar expressions, statements about the use of clinical survey data by physicians and patients and the future understanding and realization of the potential of medical cannabis in the treatment of various health conditions by the medical community worldwide.

Developing forward-looking information requires various assumptions and considerations about certain risks and uncertainties, some of which are specific to IMC and some of which are general to the industry. Risk factors and uncertainties that could cause actual results to differ materially from the expected results or expectations expressed in this press release include, without limitation, a determination that the results of the clinical survey are due to one or more factors other than medical Cannabis can be attributed to future scientific studies on the effectiveness of medicinal cannabis and peer review of the results of the clinical survey.

Readers are cautioned to carefully consider these and other factors, uncertainties and potential events and not to place undue reliance on forward-looking information. The forward-looking information contained herein was prepared as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management as of the date of this forward-looking information. The company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, or to explain material differences between actual events and such forward-looking information, unless , this is required under applicable law.

For more informations:

Ears shuster
CEO, IM Cannabis
+ 972-77-3603504
[email protected]

Caitlin Kasunich
Media relations – USA
+1 212-896-1241
[email protected]

Gal Wilder
Media Relations – Canada
+1 416-602-4092
[email protected]

Elizabeth Barker
Investor Relations
+1 212-896-1203
[email protected]

SOURCE: IM Cannabis Corp.

View source version on